5α-Reductase Inhibitors and Chemoprevention: The PCPT and Beyond

    July 2006 in “ European Urology Supplements ”
    Gerald L. Andriole
    TLDR 5α-reductase inhibitors can reduce prostate cancer risk but may increase high-grade tumors, needing more research.
    The document reviewed the role of 5α-reductase inhibitors (5-ARIs) in prostate cancer chemoprevention, particularly through studies like the Prostate Cancer Prevention Trial (PCPT) with 18,800 men, which showed a 24.8% reduction in prostate cancer prevalence with finasteride over 7 years. However, there was a noted increase in high-Gleason score tumors in the finasteride group. Other studies, such as those with dutasteride, also suggested potential benefits in reducing prostate cancer risk, though results varied. The document concluded that while 5-ARIs could lower prostate cancer risk and improve benign prostatic hyperplasia (BPH) outcomes, the increased detection of high-grade tumors required further research. It also discussed the impact of 5-ARIs on prostate cancer detection and emphasized the need for pharmacoeconomic evaluations to determine the best strategies for chemoprevention, particularly whether to focus on high-risk individuals or apply resources more broadly.
    Discuss this study in the Community →

    Research cited in this study

    2 / 2 results

    Related Community Posts Join

    6 / 161 results

      community Massive study on finasteride side effects released

      in Finasteride/Dutasteride  83 upvotes 2 years ago
      The release of a study on 5a-reductase inhibitors (finasteride and dutasteride) which showed an increased risk of depression, dementia, decreased libido, and reduced semen load as potential side effects; discussion around other forms of hair loss treatments such as topical minoxidil, RU58841, or opting to accept baldness; and advice to consider professional help for deeper issues related to hair loss.

      community EU Shouldn't Ban Fin & Dut: PFS is NOT REAL.

      in Research/Science  11 upvotes 11 months ago
      Finasteride and Dutasteride do not cause depression or "Post Finasteride Syndrome," with concerns often linked to the nocebo effect and preexisting mental health issues. The EU is unlikely to ban these drugs, but access may become more restricted due to ongoing debates.
      FCE 28260: A Forgotten 5α-Reductase Inhibitor

      community FCE 28260: A Forgotten 5α-Reductase Inhibitor

      in Research  330 upvotes 1 year ago
      FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.

      community risks with finasteride and dutasteride

      in Research/Science  141 upvotes 5 months ago
      Finasteride and dutasteride have potential risks, including post-finasteride syndrome, but are commonly used for hair loss. RU58841, minoxidil, and needling are suggested as alternatives, though all treatments carry risks.

      community Hair Loss Drugs Ranked in Order of Efficacy

      in Research/Science  67 upvotes 2 years ago
      Dutasteride is likely the most effective treatment for male pattern baldness, followed by finasteride and minoxidil in various forms and dosages. Users discuss personal experiences, dosages, and potential side effects, with some considering combining treatments for better results.

    Related Research

    6 / 6 results